Monthly Archives: July 2018

Guyana Goldfields Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Guyana Goldfields Inc. (OTC PINK: GUYFF) will be discussing their earnings results in their Q2 Earnings Call to be held on July 31, 2018 at 10:00 AM Eastern Time.

To listen to the event live or access a replay of the call – visit https://in-beta.isdrdev.com/company/C-A1B5355D98ACB.

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company’s profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on the what’s trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 507298

Novolipetsk Steel Sponsored GDR RegS to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Novolipetsk Steel Sponsored GDR RegS (OTC PINK: NISQY) will be discussing their earnings results in their Q2 Earnings Call to be held on July 31, 2018 at 10:00 AM Eastern Time.

To listen to the event live or access a replay of the call – visit https://www.investornetwork.com/company/C-D4EDE56E85C59.

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company’s profile.

About Investor Network

SOURCE: Investor Network

ReleaseID: 507299

Camtek Ltd to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Camtek Ltd (NASDAQ: CAMT) will be discussing their earnings results in their Q2 Earnings Call to be held on July 31, 2018 at 10:00 AM Eastern Time.

To listen to the event live or access a replay of the call – visit https://www.investornetwork.com/company/C-B9B1360A2610B.

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company’s profile.

About Investor Network

SOURCE: Investor Network

ReleaseID: 507305

MGX Minerals Commences Laboratory Bench-Scale Testing of Thermochemical Process to Extract Lithium from Spodumene; Case Lake Lithium Project Bulk Sample Testing Underway

VANCOUVER, BC / ACCESSWIRE / July 31, 2018 / MGX Minerals Inc. (“MGX” or the “Company”) (OTCQB: MGXMF) (CSE: XMG) (FRA: 1MG) is pleased to announce that Orion Laboratories, LLC (“Orion”) and Light Metals International Inc. (“LMI”) have commenced laboratory bench-scale testing of a 10 kilogram bulk sample of spodumene-rich rock originating from the Case Lake lithium project in Ontario. The mineralized material is currently undergoing chemical and mineralogical homogeneity testing, with the objective of extracting lithium compounds and achieving a 95% pure spodumene concentrate. Results of testing performed to date by Orion and LMI indicate that this level of spodumene purity is achievable. Once bench-scale testing has been completed to a satisfactory level, additional mineral separation testing will be conducted to further develop the hydrothermal leaching processes in order to purify high-grade spodumene concentrate.

Spodumene Concentrate Technology

MGX, Orion and LMI are jointly developing and working to commercialize a new process for extracting hard-rock lithium from spodumene concentrate. LMI has developed a thermochemical technology to rapidly manufacture lithium carbonate (Li2CO3) and/or lithium hydroxide (LiOH) from a variety of spodumene (LiAlSi2O6-rich) concentrates. The method is modular and highly scalable, thereby enabling a small “factory footprint,” and holds the potential to significantly decrease overall hard-rock lithium production costs. Unique features of the technology include:

Only three feedstock materials are required: (i) a spodumene concentrate, to produce high-purity Li2CO3 and/or high-purity LiOH; (ii) high-purity CO2, which is consumed in forming Li2CO3; and (iii) high-purity H2O, which is consumed in forming LiOH.
Creates three potentially saleable high-purity products: Li2CO3 and/or LiOH, aluminum hydroxide, Al(OH)3, and amorphous silica, SiO2.
Eliminates use of conventional sulfuric acid leaching.
Modular capabilities allow for scalable and remote deployment.

About the Partnership

MGX has agreed to acquire an initial 50% interest in the technology and associated intellectual property in exchange for an initial cash payment of US$250,000 and issuance of 100,000 common shares of the Company. Initial proceeds will be utilized to complete bench-scale laboratory testing of the technology. Upon successful completion of laboratory testing, MGX has agreed to issue an additional 250,000 common shares. Should MGX elect to further proceed, the Company will fund development of a modular manufacturing plant. Upon successful development and testing of that plant, MGX will have the option to issue an additional 500,000 shares to LMI, at which time a Joint-Venture (“JV”) will be formed with MGX holding a 70% interest and LMI a 30% interest in the JV. MGX will have the option to purchase an undivided 100% interest in the JV at any time for Can$10 million, of which LMI will have the right to choose a combination of shares and cash as consideration.

Qualified Persons

The technical portions of this press release were reviewed by Andris Kikauka (P. Geo.), Vice President of Exploration for MGX Minerals. Mr. Kikauka is a non-independent Qualified Person within the meaning of National Instrument 43-101 Standards.

About MGX Minerals

MGX Minerals is a diversified Canadian resource company with interests in advanced material and energy assets throughout North America. Learn more at www.mgxminerals.com.

Contact Information

Jared Lazerson
President and CEO
Telephone: 1.604.681.7735
Web: www.mgxminerals.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This press release contains forward-looking information or forward-looking statements (collectively “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is typically identified by words such as: “believe”, “expect”, “anticipate”, “intend”, “estimate”, “potentially” and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company is not a guarantee of future results or performance, and that actual results may differ materially from those in forward-looking information as a result of various factors. The reader is referred to the Company’s public filings for a more complete discussion of such risk factors and their potential effects which may be accessed through the Company’s profile on SEDAR at www.sedar.com.

SOURCE: MGX Minerals Inc.

ReleaseID: 507462

ENDRA Life Sciences Granted Two U.S. Patents For Correcting Fat-Induced Aberrations & Imaging Biological Tissue Structures

ANN ARBOR, MI / ACCESSWIRE / July 31, 2018 / ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ: NDRA), a developer of enhanced ultrasound technologies, has been awarded U.S. Patent Number 10,022,107 from the U.S. Patent and Trademark Office (USPTO) for “Method And System For Correcting Fat-Induced Aberrations” and U.S. Patent Number 10,028,662 from the U.S. Patent and Trademark Office (USPTO) for “Systems And Methods For Imaging Biological Tissue Structures”. ENDRA expects to utilize both inventions with its Thermo-Acoustic Enhanced Ultrasound (TAEUS™) clinical products.

The newly issued ‘107 patent covers a method and system for correcting fat-induced aberrations in conventional ultrasound imaging by utilizing thermoacoustic data of the scan region to estimate a fat map that can then be utilized by ultrasound reconstruction to correct for errors in speed of sound. ENDRA’s method and system enables improved ultrasound image quality and spatial resolution in tissue regions where fat induces artifacts conventional ultrasound reconstruction approaches. ENDRA’s method and system also potentially reduces the computation that is typically required to correct for fat related aberration.

Kai Thomenius PhD, a research scientist at the Institute of Medical Engineering & Science at The Massachusetts Institute of Technology (MIT) and co-inventor of the patent, said, “This is a novel approach to correcting fat induced image distortion in ultrasound imaging, leveraging the inherent fat and lean tissue contrast of thermoacoustics.”

The newly issued ‘662 patent covers a system and method for imaging biological tissue structures. More particularly, the ‘662 patent structurally defines an integrated ultrasound/thermoacoustic system and method which utilizes a sleeve to physically locate and register the ultrasound and thermoacoustic portions of the invention, relative to each other. The patent is a key step forward in the development of optimized hybrid ultrasound and thermoacoustic imaging systems for a wide variety of clinical applications.

The development and protection of intellectual property (“IP”) in thermoacoustic clinical applications is a key area of focus for ENDRA. To further that goal, the company currently has two patent agents embedded within the applied science team, working to define and secure IP to support ENDRA’s innovations. As of today, ENDRA’s IP portfolio totals 37 patents and patent applications that are in preparation, filed, issued or licensed, encompassing a range of device and method-focused IP in targeted global markets.

“ENDRA’s recently-issued patents directly support our efforts to commercialize a wide variety of cost-effective and non-invasive clinical application for our thermoacoustic imaging technologies,” explained ENDRA’s Chief Executive Officer, Francois Michelon.

U.S. Patent Number 10,022,107 Abstract

A method for correcting fat-induced aberrations in ultrasound imaging comprises segmenting a thermoacoustic absorption image of a region of interest into at least one fat region and at least one non-fat region, creating a speed of sound map by assigning a speed of sound to each region based on tissue type of the region, correcting aberrations in the segmented thermoacoustic absorption image using the assigned speeds of sound thereby generating a corrected thermoacoustic image, and correcting an ultrasound image of the region of interest using the corrected thermoacoustic image and the speed of sound map.

U.S. Patent Number 10,028,662 Abstract

A thermoacoustic imaging system is provided for use in combination with an ultrasound imaging system for imaging features of tissue, the ultrasound imaging system including an ultrasound imaging probe including a transmit-receive transducer array with a plurality of transmit-receive array elements. The thermoacoustic imaging system includes a receive-only transducer array with a plurality of receive-only array elements, registered with the plurality of transmit-receive array elements. The transmit-receive transducer array is housed in an ultrasound imaging probe, and the receive-only transducer array is housed in a thermoacoustic imaging probe. The thermoacoustic imaging probe is mechanically joined to the ultrasound imaging probe, e.g., as a sleeve fitted to the ultrasound imaging probe. A combined ultrasound transducer system including the ultrasound imaging probe and a thermoacoustic imaging probe may be used in composite imaging of tissue based upon the registration of the receive-only array elements with the transmit-receive array elements.

About Non-Alcoholic Fatty Liver Disease (NAFLD)

NAFLD is a condition closely associated with obesity, diabetes, hepatitis-C and certain genetic predispositions in which fat accumulates in the liver. NAFLD affects over 1 billion people globally and is estimated to cost the U.S healthcare system over $100B annually. NAFLD is often asymptomatic and, if left untreated, NAFLD can progress to inflammation (NASH), tissue scarring (fibrosis), cell death (cirrhosis) and liver cancer. By 2025, NAFLD is forecast to be the greatest root cause of liver transplants. The only tools currently available for diagnosing and monitoring NAFLD are impractical: expensive Magnetic Resonance Imaging (MRI) or an invasive surgical biopsy.

About ENDRA Life Sciences Inc.

ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ: NDRA) is a developer of enhanced ultrasound technologies. ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) platform to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI – at a fraction of the cost, and at the point-of-care. ENDRA’s first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease (NAFLD). ENDRA’s goal is to bring new capabilities to ultrasound – thereby broadening access to better healthcare. For more information, please visit www.endrainc.com.

Forward-Looking Statements

All statements in this release that are not based on historical fact are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate,” or other comparable terms. Examples of forward-looking statements include, among others, statements we make regarding the adequacy of protections afforded to us by the patents that we own and the success we may have in, and the cost to us of, maintaining, enforcing and defending those patents; expectations concerning ENDRA’s ability to secure regulatory approvals; anticipated product pricing; expectations with respect to current and future partnerships; estimates of the timing of future events and achievements; and expectations concerning ENDRA’s business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including, among others, the following: our ability to develop a commercially feasible technology; receipt of necessary regulatory approvals; our ability to find and maintain development partners; market acceptance of our technology; the amount and nature of competition in our industry; our ability to protect our intellectual property; and the other risks and uncertainties described in ENDRA’s filings with the Securities and Exchange Commission. The forward-looking statements made in this release speak only as of the date of this release, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.

CONTACT:

Company Contact:

David Wells, Chief Financial Officer
(734) 997-0464
investors@endrainc.com
www.endrainc.com

Media & Investor Relations Contact:
MZ North America
Chris Tyson, Managing Director
(949) 491-8235
NDRA@mzgroup.us
www.mzgroup.us

SOURCE: ENDRA Life Sciences Inc.

ReleaseID: 507448

Transgenic Animals Market To Expand Significantly At CAGR 8.6% During 2018-2023

The Transgenic Animals Market is estimated to grow at an approximate CAGR of 8.60% from 2017 to 2023. The global transgenic animals market is segmented on the basis of product, techniques, consumables, application, model organisms, and end-user.

Pune, India – July 31, 2018 /MarketersMedia/ —

Transgenic Animals Market Synopsis:

The modern age science and technology is reaching higher verticals with every new invention. Incorporation of technology with biology has opened up a broad pathway for research to understand and create new products with the help of genetically engineered animals. The transgenic animals are the animals that are deliberately introduced with foreign genes in their genome. As per the report that has been recently published by Market Research Future (MRFR), the global transgenic animals market is anticipated to expand significantly at a noteworthy CAGR of 8.6% during the forecast period of 2017-2023.

Market Drivers:

The rapid development in the field of genetic engineering and biotechnology is leading to the incorporation of recombinant DNA technology in various animals. The introduction of transgenic technology in cows for increasing the production of milk is gaining traction in the global market, resulting in the growth of the global transgenic animal market. The increasing use of transgenic technology for improving the quality and quantity of meat to fulfill the high demand for good quality meat in various regions of the world is one the major factors that are fueling the expansion of the global transgenic animal market.

Browse Exclusive Sample Copy of 110 Pages Report Enabled with Competitive Analysis of Niche Segments, Top Players, Comprehensive Research and Key Regions @ https://www.marketresearchfuture.com/sample_request/5464 .

The application of transgenic technology in order to cure genetic disorders and improve the breeding process of farm animals is impacting positively on the growth of the global transgenic animal market. The increasing application of transgenic animals for obtaining insulin, growth hormones, and anti-blood clotting products is fueling the growth of the global transgenic animal market.

Market Restraints:

The high cost of development of transgenic technology, reluctance in the acceptance of transgenic products and stringent regulatory framework by FDA are likely to hamper the growth of the global transgenic animal market during the forecast period.

Market Segmentation:

The global transgenic animal market has been segmented on the basis of products, techniques, consumables, application, model organisms and end-users. Based on products, the transgenic animal market is segmented into PCR, gene gun, microinjections, electroporator, and others. The PCR segment is sub-segmented into real-time PCR, digital PCR systems, and others.

Based on techniques, the transgenic animal market is segmented into retrovirus-mediated gene transfer, embryonic stem cell-mediated gene transfer, DNA microinjection, and others. Based on consumables, the transgenic animal market is segmented into fluorescent probes, culture media, and others.

Based on application, the transgenic animal market is segmented into recombinant human proteins, monoclonal antibodies, xenotransplantation, and others. Based on model organisms, the transgenic animal market is segmented into mice, rabbit, cows, and others. Based on end-users, the transgenic animal market is segmented into biotechnology industries, research organizations, academic institutes, and others.

Transgenic Animals Market Regional Analysis:

The global transgenic animal market is geographically segmented into four major regions such as Americas, Asia Pacific, Europe and the Middle East and Africa. Among these regions, the Americas is projected to be dominating the global transgenic animal market owing to the easy acceptance of transgenic products and rapid development in the field of science and technology in this region.

The Europe region holds second largest share in the global transgenic animal market owing to the increasing research and development expenditure in the field of biotechnology and genetic engineering and increasing demand for transgenic animals in this region.

The Asia Pacific region is the fastest growing market in the global transgenic animal market owing to the development of biotechnology in emerging economies such as India and China. The Middle East and Africa region accounts for the least share in the global transgenic animal market owing to the lack of technological and scientific development in the underdeveloped areas of this region.

Competitive Landscape:

The rapid development in biotechnology and genetic engineering is creating large number of opportunities for the investors in the global market, resulting in the increase in competition among the players in the global transgenic animal market. The increased research and development expenditure for introducing advanced innovations by the players is leading to the expansion of their businesses in the global transgenic animal market.

In June 2018, Ligand Pharmaceuticals Incorporated has received $47 Mn for signing an amendment with WuXi Biologics for expansion of its OmniAb antibody discovery services. OmniAb is a three-species transgenic-animal platform that uses four different technologies for producing mono and bispecific human therapeutic antibodies.

The key players of the global transgenic animal market that are profiled in the report published by MRFR are Cyagen Biosciences, Charles River, Creative-Biolabs, TRANS GENIC INC.., Ltd., Sutter Instrument Company, Bio-Rad Laboratories, Inc., Spinco Biotech Pvt Ltd., Abbott, Thermo Fisher Scientific Inc., Sigma-Aldrich Co., Accumold, and others.

Ask to Experts @ https://www.marketresearchfuture.com/enquiry/5464 .

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Info:
Name: Market Research Future
Email: sales@marketresearchfuture.com
Organization: Market Research Future
Address: Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune – 411028 Maharashtra, India
Phone: +1 646 845 9312

Source URL: https://marketersmedia.com/transgenic-animals-market-to-expand-significantly-at-cagr-8-6-during-2018-2023/386981

For more information, please visit https://www.marketresearchfuture.com/reports/transgenic-animals-market-5464

Source: MarketersMedia

Release ID: 386981

Today’s Research Reports on Trending Tickers: Tandem Diabetes Care and NuVasive

NEW YORK, NY / ACCESSWIRE / July 31, 2018 / U.S. markets continued to drop on Monday, as tech sector close in the red weighed by majority of the FAANG (Facebook, Apple, Amazon, Netflix and Google parent Alphabet) stocks. The Dow Jones Industrial Average fell 0.57 percent to close at 25,306.83, while the S&P 500 Index was down 0.58 percent to close at 2,802.60. The Nasdaq Composite Index declined 1.39 percent to close at 7,630.00.

“The market is punishing companies that don’t beat on revenue or earnings, or which give a bad outlook. You need to win on all three to do well, and if you miss, like Facebook did, you get pummeled,” said director of global market research at Boston Partners, Michael Mullaney.

RDI Initiates Coverage on:

Tandem Diabetes Care, Inc.
https://rdinvesting.com/news/?ticker=TNDM

NuVasive, Inc.
https://rdinvesting.com/news/?ticker=NUVA

Tandem Diabetes Care’s stock moved 2.97% lower Monday, to close the day at $24.84. The stock recorded a trading volume of 1,840,930 shares, which was below its three months average volume of 2,593,415 shares. In the last year, Tandem Diabetes Care’s shares have traded in a range of 2.14 – 28.90. The share price has gained 1060.75% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $23.16 is above its 200-day moving average of $10.54. Shares of Tandem Diabetes Care have gained roughly 12.81 percent in the past month and are up 952.54 percent year-to-date.

Access RDI’s Tandem Diabetes Care, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=TNDM

On Monday, shares of NuVasive recorded a trading volume of 1,448,100 shares, which was above the three months average volume of 596,164 shares. The stock ended the day 6.02% higher at $57.22. The share price has fallen 16.73% from its 52 week high with a 52 week trading range of 44.62 – 68.72. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $53.76 is above its 200-day moving average of $51.53. Shares of the company are trading at a Price to Earnings ratio of 71.35. Shares of NuVasive have gained roughly 9.79 percent in the past month and are down 2.17 percent year-to-date.

Access RDI’s NuVasive, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=NUVA

Our Actionable Research on Tandem Diabetes Care, Inc. (NASDAQ:TNDM) and NuVasive, Inc. (NASDAQ:NUVA) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 507500

Today’s Research Reports on Trending Tickers: Denbury Resources and Chesapeake Energy

RDI Initiates Coverage on:

Denbury Resources Inc.
https://rdinvesting.com/news/?ticker=DNR

Chesapeake Energy Corporation
https://rdinvesting.com/news/?ticker=CHK

Denbury Resources’ stock jumped 11.69% Monday, to close the day at $4.68. The stock recorded a trading volume of 12,804,104 shares, which was above its three months average volume of 12,690,588 shares. In the last year, Denbury Resources’ shares have traded in a range of 0.91 – 5.56. The share price has gained 414.29% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $4.57 is above its 200-day moving average of $3.34. Shares of the company are trading at a Price to Earnings ratio of 10.52. Shares of Denbury Resources have fallen roughly 2.7 percent in the past month and are up 111.76 percent year-to-date.

Access RDI’s Denbury Resources Inc. Research Report at:
https://rdinvesting.com/news/?ticker=DNR

On Monday, shares of Chesapeake Energy recorded a trading volume of 37,550,684 shares, which was below the three months average volume of 39,542,887 shares. The stock ended the day 5.9% higher at $4.67. The share price has fallen 16.61% from its 52 week high with a 52 week trading range of 2.53 – 5.60. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $4.90 is above its 200-day moving average of $3.77. Shares of Chesapeake Energy have fallen roughly 10.88 percent in the past month and are up 17.93 percent year-to-date.

Access RDI’s Chesapeake Energy Corporation Research Report at:
https://rdinvesting.com/news/?ticker=CHK

Our Actionable Research on Denbury Resources Inc. (NYSE :DNR) and Chesapeake Energy Corporation (NYSE :CHK) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 507501

Today’s Research Reports on Trending Tickers: Bristol-Myers Squibb and Allergan

RDI Initiates Coverage on:

Bristol-Myers Squibb Company
https://rdinvesting.com/news/?ticker=BMY

Allergan plc
https://rdinvesting.com/news/?ticker=AGN

Bristol-Myers Squibb’s stock jumped 3.53% Monday, to close the day at $58.93. The stock recorded a trading volume of 8,096,923 shares, which was above its three months average volume of 7,129,855 shares. In the last year, Bristol-Myers Squibb’s shares have traded in a range of 49.96 – 70.05. The share price has gained 17.95% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $55.59 is below its 200-day moving average of $58.58. Shares of the company are trading at a Price to Earnings ratio of 105.04. Shares of Bristol-Myers Squibb have gained roughly 6.49 percent in the past month and are down 3.83 percent year-to-date.

Access RDI’s Bristol-Myers Squibb Company Research Report at:
https://rdinvesting.com/news/?ticker=BMY

On Monday, shares of Allergan recorded a trading volume of 2,982,683 shares, which was above the three months average volume of 2,360,412 shares. The stock ended the day 3.01% higher at $183.99. The share price has fallen 27.99% from its 52 week high with a 52 week trading range of 142.81 – 255.52. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $173.07 is above its 200-day moving average of $165.10. Shares of Allergan have gained roughly 10.36 percent in the past month and are up 12.48 percent year-to-date.

Access RDI’s Allergan plc Research Report at:
https://rdinvesting.com/news/?ticker=AGN

Our Actionable Research on Bristol-Myers Squibb Company (NYSE :BMY) and Allergan plc (NYSE :AGN) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 507502

Today’s Research Reports on Trending Tickers: Shopify and LogMeIn

RDI Initiates Coverage on:

Shopify Inc.
https://rdinvesting.com/news/?ticker=SHOP

LogMeIn, Inc.
https://rdinvesting.com/news/?ticker=LOGM

Shopify’s stock moved 7.54% lower Monday, to close the day at $148.08. The stock recorded a trading volume of 2,745,106 shares, which was above its three months average volume of 1,508,998 shares. In the last year, Shopify’s shares have traded in a range of 88.21 – 176.60. The share price has gained 67.87% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $162.67 is above its 200-day moving average of $140.88. Shares of Shopify have gained roughly 1.50 percent in the past month and are up 46.61 percent year-to-date.

Access RDI’s Shopify Inc. Research Report at:
https://rdinvesting.com/news/?ticker=SHOP

On Monday, shares of LogMeIn recorded a trading volume of 2,509,011 shares, which was above the three months average volume of 663,006 shares. The stock ended the day 4.37% higher at $81.25. The share price has fallen 39.73% from its 52 week high with a 52 week trading range of 77.05 – 134.80. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $106.54 is below its 200-day moving average of $115.12. Shares of the company are trading at a Price to Earnings ratio of 29.61. Shares of LogMeIn have fallen roughly 21.31 percent in the past month and are down 29.04 percent year-to-date.

Access RDI’s LogMeIn, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=LOGM

Our Actionable Research on Shopify Inc. (NYSE:SHOP) and LogMeIn, Inc. (NASDAQ:LOGM) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 507503